Eating Disorders & GLP-1 RAs

PDF Available ?

Yes

Year

2025

Glucagon-like peptide-1receptor agonists (GLP-1 RAs), such as semaglutide (Ozempic), are medications originally developed to treat type 2 diabetes. LP-1 RAs are now being used as an approved or off-label treatment for weight loss.

here is limited research available to help researchers, clinicians, and patients/consumers to understand the relationships between GLP-1 RAs and eating disorders (9). However, it is thought that GLP-1 RAs may negatively impact eating disorder symptomology and treatment in a number of ways.

This factsheet provides information for clinicians, researchers, and patients/consumers to understand more about the link between GLP-1 RAs and eating disorders, including risks, physical impacts, psychological impacts, and practice recommendations.

« Back to Browse Resources

See also

NSW Health Mental Health for Emergency Departments – A reference guide

Read more

AED Eating Disorders: A Guide to Medical Care (4th Ed.)

Often referred to as, the purple book, this guide from the Academy for Eating Disorders' (AED) Medical Care Standards Committee, is intended as a resource to promote recognition and risk management in the care of those with eating disorders.

Read more

Summary paper - NDIS engagement for people with eating disorders

The National Disability Insurance Scheme (NDIS) has been operational in Australia for ten years.

Read more

Assessment & treatment of children and adolescents with eating disorders in Queensland

The aim of this guideline is to assist staff within Queensland Health Child and Youth Mental Health Services (CYMHS), Departments of Emergency Medicine, inpatient mental health units and paediatric medical wards when assessing a child or adolescent with a possible eating disorder, and deciding the most appropriate placement, treatment and care for the child or adolescent where admission to hospital is required.

Read more